Antibiotic resistance focus SciBac specializes in live biotherapeutics targeting antibiotic resistant infections, presenting a clear growth area for partnerships with hospitals, health systems, and payer-backed initiatives seeking alternatives to traditional antibiotics.

C difficile pipeline The first product targets Clostridium difficile infection, a high-need market with substantial recurrence risk, offering opportunities to engage with ID physicians, gastroenterologists, and hospital procurement for infection control programs.

Non-GMO platform DRIVE technology enabling non-GMO hybrid microorganisms creates potential collaboration with biotech and enzyme companies seeking cost-efficient expression systems, licensing deals, or joint development in microbiome therapies.

NIH grant traction Recent NIH funding signals validated research credibility; leverage to approach government-funded research programs, biotech investors, and grant-aligned venture studios for co-development or milestone-based financing.

Early-stage funding & revenue With modest revenue and early-stage funding, there is an opportunity to pursue strategic partnerships with larger biotech players for co-development, supply agreements, or potential acquisition discussions as the platform scales.